## Christopher E Kvistad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6411839/publications.pdf

Version: 2024-02-01

42 papers 1,060 citations

567281 15 h-index 31 g-index

43 all docs 43 docs citations

43 times ranked

1434 citing authors

#	Article	IF	Citations
1	Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurology, The, 2017, 16, 781-788.	10.2	305
2	Recurrent ischemic stroke: Incidence, predictors, and impact on mortality. Acta Neurologica Scandinavica, 2019, 140, 3-8.	2.1	94
3	Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2,) Tj ETQq1 The, 2022, 21, 511-519.	1 0.78431 10.2	14 rgBT /Ov <mark>er</mark> 88
4	NOR-SASS (Norwegian Sonothrombolysis in Acute Stroke Study). Stroke, 2017, 48, 335-341.	2.0	52
5	When to Screen Ischaemic Stroke Patients for Cancer. Cerebrovascular Diseases, 2018, 45, 42-47.	1.7	47
6	The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke. BMC Neurology, 2014, 14, 106.	1.8	44
7	Elevated Admission Blood Pressure and Stroke Severity in Acute Ischemic Stroke: The Bergen NORSTROKE Study. Cerebrovascular Diseases, 2013, 36, 351-354.	1.7	35
8	Mild stroke: safety and outcome in patients receiving thrombolysis. Acta Neurologica Scandinavica, 2014, 129, 37-40.	2.1	33
9	Therapeutic Potential of Tenecteplase in the Management of Acute Ischemic Stroke. CNS Drugs, 2015, 29, 811-818.	5.9	31
10	Safety of off-label stroke treatment with tissue plasminogen activator. Acta Neurologica Scandinavica, 2013, 128, 48-53.	2.1	29
11	Safety and Outcomes of Tenecteplase in Moderate and Severe Ischemic Stroke. Stroke, 2019, 50, 1279-1281.	2.0	29
12	Intravenous Thrombolysis in Ischemic Stroke Patients With Active Cancer. Frontiers in Neurology, 2018, 9, 811.	2.4	22
13	Is smoking associated with favourable outcome in tPA-treated stroke patients?. Acta Neurologica Scandinavica, 2014, 130, 299-304.	2.1	21
14	Thirtyâ€day recurrence after ischemic stroke or TIA. Brain and Behavior, 2018, 8, e01108.	2.2	16
15	Body temperature and major neurological improvement in tPA-treated stroke patients. Acta Neurologica Scandinavica, 2014, 129, 325-329.	2.1	15
16	Diffusion-weighted lesions in acute ischaemic stroke patients with migraine. Acta Neurologica Scandinavica, 2014, 129, 41-46.	2.1	15
17	A pragmatic approach to sonothrombolysis in acute ischaemic stroke: the Norwegian randomised controlled sonothrombolysis in acute stroke study (NOR-SASS). BMC Neurology, 2015, 15, 110.	1.8	15
18	Safety and predictors of stroke mimics in The Norwegian Tenecteplase Stroke Trial (NOR-TEST). International Journal of Stroke, 2019, 14, 508-516.	5.9	15

#	Article	IF	Citations
19	Tenecteplase Versus Alteplase Between 3 and 4.5 Hours in Low National Institutes of Health Stroke Scale. Stroke, 2019, 50, 498-500.	2.0	15
20	Low body temperature associated with severe ischemic stroke within 6 hours of onset: The Bergen NORSTROKE Study. Vascular Health and Risk Management, 2012, 8, 333.	2.3	14
21	A stress-related explanation to the increased blood pressure and its course following ischemic stroke. Vascular Health and Risk Management, 2016, Volume 12, 435-442.	2.3	11
22	Tenecteplase versus alteplase after acute ischemic stroke at high age. International Journal of Stroke, 2021, 16, 295-299.	5.9	11
23	Clinical implications of increased use of MRI in TIA. Acta Neurologica Scandinavica, 2013, 128, 32-38.	2.1	10
24	Incidence and Etiologies of Stroke Mimics After Incident Stroke or Transient Ischemic Attack. Stroke, 2019, 50, 2937-2940.	2.0	10
25	Short-Term Outcome and In-Hospital Complications After Acute Cerebral Infarcts in Multiple Arterial Territories. Stroke, 2019, 50, 3625-3627.	2.0	10
26	Uâ€shaped relationship between hemoglobin level and severity of ischemic stroke. Acta Neurologica Scandinavica, 2019, 140, 56-61.	2.1	8
27	Diffusion-Weighted Lesions in Stroke Patients with Transient Symptoms - Where Are They Located?. Cerebrovascular Diseases, 2014, 38, 219-225.	1.7	7
28	Is higher body temperature beneficial in ischemic stroke patients with normal admission CT angiography of the cerebral arteries?. Vascular Health and Risk Management, 2014, 10, 49.	2.3	6
29	Novel Thrombolytics for Acute Ischemic Stroke: Challenges and Opportunities. CNS Drugs, 2016, 30, 101-108.	5.9	6
30	Elevated body temperature in ischemic stroke associated with neurological improvement. Acta Neurologica Scandinavica, 2017, 136, 414-418.	2.1	6
31	Persistent Microembolic Signals in the Cerebral Circulation on Transcranial Doppler after Intravenous Sulfur Hexafluoride Microbubble Infusion. Journal of Neuroimaging, 2020, 30, 146-149.	2.0	6
32	A score for paroxysmal atrial fibrillation in acute ischemic stroke. International Journal of Stroke, 2018, 13, 496-502.	5.9	5
33	A Family History of Stroke Is Associated with Increased Intima-Media Thickness in Young Ischemic Stroke - The Norwegian Stroke in the Young Study (NOR-SYS). PLoS ONE, 2016, 11, e0159811.	2.5	5
34	Does a History of Migraine Affect the Rate of Thrombolysis in Young Stroke Patients?. Stroke Research and Treatment, 2013, 2013, 1-5.	0.8	3
35	Persistent middle cerebral artery occlusion associated with lower body temperature on admission. Vascular Health and Risk Management, 2013, 9, 297.	2.3	3
36	High risk of early neurological worsening of lacunar infarction. Acta Neurologica Scandinavica, 2019, 139, 143-149.	2.1	3

#	Article	IF	CITATION
37	Clinical manifestation of acute cerebral infarcts in multiple arterial territories. Brain and Behavior, 2021, 11, e2296.	2.2	3
38	The Course of Carotid Plaque Vulnerability Assessed by Advanced Neurosonology. Frontiers in Neurology, 2021, 12, 702657.	2.4	3
39	A Dark Side of Subcortical Diffusion-Weighted Lesions?. Stroke, 2014, 45, 2710-2716.	2.0	2
40	Contrastâ€enhanced sonothrombolysis in acute ischemic stroke patients without intracranial largeâ€vessel occlusion. Acta Neurologica Scandinavica, 2018, 137, 256-261.	2.1	2
41	Sex Differences in the Norwegian Tenecteplase Trial (NORâ€TEST). European Journal of Neurology, 2021, ,	3.3	2
42	Clinical Importance of Temporal Bone Features for the Efficacy of Contrast-Enhanced Sonothrombolysis: a Retrospective Analysis of the NOR-SASS Trial. Translational Stroke Research, 2018, 9, 333-339.	4.2	1